Trial Profile
An Open Label, Phase I/II Study to Evaluate the Safety and Efficacy of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor Given in Combination With a Histone Deacetylase (HDAC) Inhibitor, Romidepsin in Adult Patients With Relapsed/Refractory T-cell Lymphoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 01 Nov 2022
Price :
$35
*
At a glance
- Drugs Romidepsin (Primary) ; Tenalisib (Primary)
- Indications Cutaneous T-cell lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
- Focus Adverse reactions
- Sponsors Rhizen Pharmaceuticals
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 27 Sep 2021 Status changed from active, no longer recruiting to completed.
- 12 Mar 2021 Planned primary completion date changed from 1 Dec 2020 to 1 May 2021.